APO-IMIPRAMINE TABLETS 75 MG
IMIPRAMINE HYDROCHLORIDE : 75 MG · DIN 00644579 · APOTEX INC
Health Canada status: MARKETED
What is APO-IMIPRAMINE TABLETS?
APO-IMIPRAMINE TABLETS 75 MG contains IMIPRAMINE HYDROCHLORIDE : 75 MG. It is listed in the Health Canada Drug Product Database under DIN 00644579, held by APOTEX INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 20-Jan-2026. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is APO-IMIPRAMINE TABLETS used for?
Relief of symptoms of depressive illness. Not indicated for mild depressive states or depressive reactions.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 00644579 |
|---|---|
| Brand name | APO-IMIPRAMINE TABLETS |
| Generic / active ingredient | IMIPRAMINE HYDROCHLORIDE : 75 MG |
| Manufacturer | APOTEX INC |
| Strength | 75 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N06AA02 IMIPRAMINE |
| AHFS class | 28:16.04.28 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 20-Jan-2026 |
| Original market date | 1989-12-31 00:00:00 |
How is it administered?
Adults: Initial 25 mg tid, increase to 150 mg/day. Max 200 mg/day (outpatients) or 300 mg/day (hospitalized). Elderly: 30-40 mg/day initially, max 100 mg/day. Swallow whole with water.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly stated in provided text (refer to section 11 of full monograph). Typical TCA storage is 15-30°C.
How is it supplied?
Bottles of 100 or 1000 tablets.
Contraindications
Hypersensitivity to imipramine or TCAs; concurrent MAOI use (within 14 days); acute recovery post-myocardial infarction; acute congestive heart failure; narrow angle glaucoma.
Warnings and precautions
QT prolongation, arrhythmia, hypotension, suicide risk, seizure risk, Brugada syndrome unmasking, anticholinergic effects (urinary retention, glaucoma), and withdrawal symptoms.
What can be used instead?
Other Canadian products sharing ATC code N06AA02 IMIPRAMINE. 8 of 32 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-IMIPRAMINE TABLETS | 10 MG | TABLET | APOTEX INC | MARKETED | DIN 00360201 |
| APO-IMIPRAMINE TABLETS | 25 MG | TABLET | APOTEX INC | MARKETED | DIN 00312797 |
| APO-IMIPRAMINE TABLETS | 50 MG | TABLET | APOTEX INC | MARKETED | DIN 00326852 |
| JAMP IMIPRAMINE | 10 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02546337 |
| JAMP IMIPRAMINE | 25 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02546345 |
| JAMP IMIPRAMINE | 50 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02546353 |
| JAMP IMIPRAMINE | 75 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02546361 |
| APO-IMIPRAMINE | 10 MG | TABLET | APOTEX INC | APPROVED | DIN 02406586 |
| APO-IMIPRAMINE | 25 MG | TABLET | APOTEX INC | APPROVED | DIN 02406594 |
| APO-IMIPRAMINE | 50 MG | TABLET | APOTEX INC | APPROVED | DIN 02406608 |
Who else supplies IMIPRAMINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. IMIPRAMINE appears in 17 registered pack listings across 5 markets, published on 4 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.